Sökning: onr:"swepub:oai:DiVA.org:umu-176925" >
Enzalutamide and Su...
-
Sternberg, Cora N.
(författare)
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- Artikel/kapitelEngelska2020
Förlag, utgivningsår, omfång ...
-
Massachusetts Medical Society,2020
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:umu-176925
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-176925URI
-
https://doi.org/10.1056/NEJMoa2003892DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-deprivation therapy. Results from the final analysis of overall survival have not yet been reported.Methods: In this double-blind, phase 3 trial, men with nonmetastatic, castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of ≤10 months) who were continuing to receive androgen-deprivation therapy were randomly assigned (in a 2:1 ratio) to receive enzalutamide at a dose of 160 mg or placebo once daily. Overall survival was assessed with a group sequential testing procedure and an O’Brien–Fleming–type alpha-spending function.Results: As of October 15, 2019, a total of 288 of 933 patients (31%) in the enzalutamide group and 178 of 468 (38%) in the placebo group had died. Median overall survival was 67.0 months (95% confidence interval [CI], 64.0 to not reached) in the enzalutamide group and 56.3 months (95% CI, 54.4 to 63.0) in the placebo group (hazard ratio for death, 0.73; 95% CI, 0.61 to 0.89; P=0.001). The exposure-adjusted rate of adverse events of grade 3 or higher was 17 per 100 patient-years in the enzalutamide group and 20 per 100 patient-years in the placebo group. Adverse events in the enzalutamide group were consistent with those previously reported for enzalutamide; the most frequently reported events were fatigue and musculoskeletal events.Conclusions: Enzalutamide plus androgen-deprivation therapy resulted in longer median overall survival than placebo plus androgen-deprivation therapy among men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level. The risk of death associated with enzalutamide was 27% lower than with placebo. Adverse events were consistent with the established safety profile of enzalutamide. (Funded by Pfizer and Astellas Pharma; PROSPER ClinicalTrials.gov number, NCT02003924.)
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Fizazi, Karim
(författare)
-
Saad, Fred
(författare)
-
Shore, Neal D.
(författare)
-
De Giorgi, Ugo
(författare)
-
Penson, David F.
(författare)
-
Ferreira, Ubirajara
(författare)
-
Efstathiou, Eleni
(författare)
-
Madziarska, Katarzyna
(författare)
-
Kolinsky, Michael P.
(författare)
-
Cubero, Daniel I. G.
(författare)
-
Noerby, Bettina
(författare)
-
Zohren, Fabian
(författare)
-
Lin, Xun
(författare)
-
Modelska, Katharina
(författare)
-
Sugg, Jennifer
(författare)
-
Steinberg, Joyce
(författare)
-
Hussain, Maha
(författare)
-
Bjartell, AndersUmeå universitet,Institutionen för kirurgisk och perioperativ vetenskap(Swepub:umu)anbj0196
(bidragsgivare)
-
Ljungberg, Börje,Professor,1949-Umeå universitet,Urologi och andrologi(Swepub:umu)bolj0001
(bidragsgivare)
-
Umeå universitetInstitutionen för kirurgisk och perioperativ vetenskap
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:New England Journal of Medicine: Massachusetts Medical Society382:23, s. 2197-22060028-47931533-4406
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Sternberg, Cora ...
-
Fizazi, Karim
-
Saad, Fred
-
Shore, Neal D.
-
De Giorgi, Ugo
-
Penson, David F.
-
visa fler...
-
Ferreira, Ubiraj ...
-
Efstathiou, Elen ...
-
Madziarska, Kata ...
-
Kolinsky, Michae ...
-
Cubero, Daniel I ...
-
Noerby, Bettina
-
Zohren, Fabian
-
Lin, Xun
-
Modelska, Kathar ...
-
Sugg, Jennifer
-
Steinberg, Joyce
-
Hussain, Maha
-
Bjartell, Anders
-
Ljungberg, Börje ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
New England Jour ...
- Av lärosätet
-
Umeå universitet